Novo Nordisk A/S (NONOF)
OTCMKTS
· Delayed Price · Currency is USD
75.00
+1.90 (2.59%)
Jun 6, 2025, 10:09 AM EDT
Novo Nordisk Revenue
Novo Nordisk had revenue of 78.09B DKK in the quarter ending March 31, 2025, with 19.49% growth. This brings the company's revenue in the last twelve months to 303.14B, up 24.11% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
303.14B DKK
Revenue Growth
+24.11%
P/S Ratio
7.57
Revenue / Employee
3.92M DKK
Employees
77,349
Market Cap
332.47B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
American Oncology Network | 1.76B |
Novo Nordisk News
- 12 hours ago - Novo Nordisk Stock: Is It Still a Smart Buy? - The Motley Fool
- 3 days ago - What's Going On With Novo Nordisk Shares Today? - Benzinga
- 3 days ago - Report finds an alarming rise in Wegovy use among U.S. teens - Seeking Alpha
- 3 days ago - Florida Rep. Scott Franklin Bought Up to $15K Worth of Union Pacific Stock - Benzinga
- 4 days ago - Novo Nordisk faces fierce competition in China’s diabetes drug market - South China Morning Post
- 7 days ago - The boomerang era: A slew of former CEOs are suiting up once more to take top roles at their old companies - Fortune
- 8 days ago - Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly - Investor's Business Daily
- 8 days ago - Novo Nordisk's weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly's Zepbound, and now the company is trying to get back on track - WSJ